Baidu
map

J Asthma Allergy:手术在治疗鼻塞和控制哮喘中的作用

2020-12-26 AlexYang MedSci原创

大多数哮喘患者,无论是过敏性或非过敏性的,通常都会表现出某种水平的并发鼻炎。鼻炎和哮喘的治疗均会对两种疾病产生影响。

大多数哮喘患者,无论是过敏性或非过敏性的,通常都会表现出某种水平的并发鼻炎。鼻炎和哮喘的治疗均会对两种疾病产生影响。

最近,有研究人员调查了慢性鼻炎(CR)和哮喘患者在鼻腔阻塞手术后的哮喘特异性结果,并确定最有可能在手术后能够改善哮喘控制的患者群体。研究人员前瞻性地招募了患有CR和鼻阻塞的哮喘患者,评估了鼻阻塞手术前和手术后的鼻腔和哮喘特定结果。研究共包括了28名参与者。在术前和术后3个月的评估中发现,哮喘控制测试(ACT)和鼻腔鼻窦结果测试-22评分之间存在显著关联。鼻腔手术后表现出ACT改善的患者术前ACT评分和预测的1秒内强迫呼气量更差。

鼻手术改善鼻腔鼻窦症状(A),而不改善哮喘控制(B),以及哮喘控制药物使用情况(C)

最后,研究人员指出,鼻部症状严重程度与CR和鼻腔阻塞的哮喘患者的哮喘控制程度密切相关。对控制不佳的哮喘患者进行CR和鼻阻塞的评估应考虑作为为改善治疗响应和患者生活质量的重要方法。

原始出处:

Pei-Wen Wu , Ta-Jen Lee , Chun-Hua Wang et al. The Role of Surgery in Treating Nasal Obstruction to Control Asthma. J Asthma Allergy. 2020

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (7)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1712649, encodeId=8c091e12649a1, content=<a href='/topic/show?id=9a1c289680' target=_blank style='color:#2F92EE;'>#AST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2896, encryptionId=9a1c289680, topicName=AST)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8b9831894722, createdName=ms24272190615788285182, createdTime=Tue Sep 07 01:56:42 CST 2021, time=2021-09-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1977162, encodeId=a54419e716258, content=<a href='/topic/show?id=0081289832' target=_blank style='color:#2F92EE;'>#asthma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2898, encryptionId=0081289832, topicName=asthma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9b30126, createdName=skhzy, createdTime=Wed Aug 04 22:56:42 CST 2021, time=2021-08-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1329447, encodeId=9a07132944e2d, content=<a href='/topic/show?id=bb96232801' target=_blank style='color:#2F92EE;'>#ALL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2328, encryptionId=bb96232801, topicName=ALL)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/C2EFD5CFB07FE291138AD4FD0C98E3DE/100, createdBy=e3d52500031, createdName=膀胱癌, createdTime=Mon Dec 28 06:56:42 CST 2020, time=2020-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1361147, encodeId=89ac136114eaf, content=<a href='/topic/show?id=3e891034351c' target=_blank style='color:#2F92EE;'>#鼻塞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103435, encryptionId=3e891034351c, topicName=鼻塞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6779163, createdName=liuhuangbo, createdTime=Mon Dec 28 06:56:42 CST 2020, time=2020-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=911453, encodeId=d01f911453bc, content=很好的文章,学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=115, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201226/95ac6d022b194200b46211c8dd67d7d4/d7639abce33d42f18edacbf9c1818b2b.jpg, createdBy=1c242248512, createdName=医路顺丰, createdTime=Sun Dec 27 22:41:06 CST 2020, time=2020-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=911212, encodeId=44a291121214, content=学习了。, beContent=null, objectType=article, channel=null, level=null, likeNumber=146, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d6274853329, createdName=936368183, createdTime=Sun Dec 27 10:49:47 CST 2020, time=2020-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=911125, encodeId=f18d911125a1, content=好文章!, beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160806/IMG57A5698BDB0244113.jpg, createdBy=32a91358059, createdName=jyzxjiangqin, createdTime=Sat Dec 26 19:10:02 CST 2020, time=2020-12-26, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1712649, encodeId=8c091e12649a1, content=<a href='/topic/show?id=9a1c289680' target=_blank style='color:#2F92EE;'>#AST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2896, encryptionId=9a1c289680, topicName=AST)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8b9831894722, createdName=ms24272190615788285182, createdTime=Tue Sep 07 01:56:42 CST 2021, time=2021-09-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1977162, encodeId=a54419e716258, content=<a href='/topic/show?id=0081289832' target=_blank style='color:#2F92EE;'>#asthma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2898, encryptionId=0081289832, topicName=asthma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9b30126, createdName=skhzy, createdTime=Wed Aug 04 22:56:42 CST 2021, time=2021-08-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1329447, encodeId=9a07132944e2d, content=<a href='/topic/show?id=bb96232801' target=_blank style='color:#2F92EE;'>#ALL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2328, encryptionId=bb96232801, topicName=ALL)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/C2EFD5CFB07FE291138AD4FD0C98E3DE/100, createdBy=e3d52500031, createdName=膀胱癌, createdTime=Mon Dec 28 06:56:42 CST 2020, time=2020-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1361147, encodeId=89ac136114eaf, content=<a href='/topic/show?id=3e891034351c' target=_blank style='color:#2F92EE;'>#鼻塞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103435, encryptionId=3e891034351c, topicName=鼻塞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6779163, createdName=liuhuangbo, createdTime=Mon Dec 28 06:56:42 CST 2020, time=2020-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=911453, encodeId=d01f911453bc, content=很好的文章,学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=115, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201226/95ac6d022b194200b46211c8dd67d7d4/d7639abce33d42f18edacbf9c1818b2b.jpg, createdBy=1c242248512, createdName=医路顺丰, createdTime=Sun Dec 27 22:41:06 CST 2020, time=2020-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=911212, encodeId=44a291121214, content=学习了。, beContent=null, objectType=article, channel=null, level=null, likeNumber=146, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d6274853329, createdName=936368183, createdTime=Sun Dec 27 10:49:47 CST 2020, time=2020-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=911125, encodeId=f18d911125a1, content=好文章!, beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160806/IMG57A5698BDB0244113.jpg, createdBy=32a91358059, createdName=jyzxjiangqin, createdTime=Sat Dec 26 19:10:02 CST 2020, time=2020-12-26, status=1, ipAttribution=)]
    2021-08-04 skhzy
  3. [GetPortalCommentsPageByObjectIdResponse(id=1712649, encodeId=8c091e12649a1, content=<a href='/topic/show?id=9a1c289680' target=_blank style='color:#2F92EE;'>#AST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2896, encryptionId=9a1c289680, topicName=AST)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8b9831894722, createdName=ms24272190615788285182, createdTime=Tue Sep 07 01:56:42 CST 2021, time=2021-09-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1977162, encodeId=a54419e716258, content=<a href='/topic/show?id=0081289832' target=_blank style='color:#2F92EE;'>#asthma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2898, encryptionId=0081289832, topicName=asthma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9b30126, createdName=skhzy, createdTime=Wed Aug 04 22:56:42 CST 2021, time=2021-08-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1329447, encodeId=9a07132944e2d, content=<a href='/topic/show?id=bb96232801' target=_blank style='color:#2F92EE;'>#ALL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2328, encryptionId=bb96232801, topicName=ALL)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/C2EFD5CFB07FE291138AD4FD0C98E3DE/100, createdBy=e3d52500031, createdName=膀胱癌, createdTime=Mon Dec 28 06:56:42 CST 2020, time=2020-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1361147, encodeId=89ac136114eaf, content=<a href='/topic/show?id=3e891034351c' target=_blank style='color:#2F92EE;'>#鼻塞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103435, encryptionId=3e891034351c, topicName=鼻塞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6779163, createdName=liuhuangbo, createdTime=Mon Dec 28 06:56:42 CST 2020, time=2020-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=911453, encodeId=d01f911453bc, content=很好的文章,学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=115, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201226/95ac6d022b194200b46211c8dd67d7d4/d7639abce33d42f18edacbf9c1818b2b.jpg, createdBy=1c242248512, createdName=医路顺丰, createdTime=Sun Dec 27 22:41:06 CST 2020, time=2020-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=911212, encodeId=44a291121214, content=学习了。, beContent=null, objectType=article, channel=null, level=null, likeNumber=146, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d6274853329, createdName=936368183, createdTime=Sun Dec 27 10:49:47 CST 2020, time=2020-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=911125, encodeId=f18d911125a1, content=好文章!, beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160806/IMG57A5698BDB0244113.jpg, createdBy=32a91358059, createdName=jyzxjiangqin, createdTime=Sat Dec 26 19:10:02 CST 2020, time=2020-12-26, status=1, ipAttribution=)]
    2020-12-28 膀胱癌
  4. [GetPortalCommentsPageByObjectIdResponse(id=1712649, encodeId=8c091e12649a1, content=<a href='/topic/show?id=9a1c289680' target=_blank style='color:#2F92EE;'>#AST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2896, encryptionId=9a1c289680, topicName=AST)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8b9831894722, createdName=ms24272190615788285182, createdTime=Tue Sep 07 01:56:42 CST 2021, time=2021-09-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1977162, encodeId=a54419e716258, content=<a href='/topic/show?id=0081289832' target=_blank style='color:#2F92EE;'>#asthma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2898, encryptionId=0081289832, topicName=asthma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9b30126, createdName=skhzy, createdTime=Wed Aug 04 22:56:42 CST 2021, time=2021-08-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1329447, encodeId=9a07132944e2d, content=<a href='/topic/show?id=bb96232801' target=_blank style='color:#2F92EE;'>#ALL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2328, encryptionId=bb96232801, topicName=ALL)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/C2EFD5CFB07FE291138AD4FD0C98E3DE/100, createdBy=e3d52500031, createdName=膀胱癌, createdTime=Mon Dec 28 06:56:42 CST 2020, time=2020-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1361147, encodeId=89ac136114eaf, content=<a href='/topic/show?id=3e891034351c' target=_blank style='color:#2F92EE;'>#鼻塞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103435, encryptionId=3e891034351c, topicName=鼻塞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6779163, createdName=liuhuangbo, createdTime=Mon Dec 28 06:56:42 CST 2020, time=2020-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=911453, encodeId=d01f911453bc, content=很好的文章,学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=115, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201226/95ac6d022b194200b46211c8dd67d7d4/d7639abce33d42f18edacbf9c1818b2b.jpg, createdBy=1c242248512, createdName=医路顺丰, createdTime=Sun Dec 27 22:41:06 CST 2020, time=2020-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=911212, encodeId=44a291121214, content=学习了。, beContent=null, objectType=article, channel=null, level=null, likeNumber=146, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d6274853329, createdName=936368183, createdTime=Sun Dec 27 10:49:47 CST 2020, time=2020-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=911125, encodeId=f18d911125a1, content=好文章!, beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160806/IMG57A5698BDB0244113.jpg, createdBy=32a91358059, createdName=jyzxjiangqin, createdTime=Sat Dec 26 19:10:02 CST 2020, time=2020-12-26, status=1, ipAttribution=)]
    2020-12-28 liuhuangbo
  5. [GetPortalCommentsPageByObjectIdResponse(id=1712649, encodeId=8c091e12649a1, content=<a href='/topic/show?id=9a1c289680' target=_blank style='color:#2F92EE;'>#AST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2896, encryptionId=9a1c289680, topicName=AST)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8b9831894722, createdName=ms24272190615788285182, createdTime=Tue Sep 07 01:56:42 CST 2021, time=2021-09-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1977162, encodeId=a54419e716258, content=<a href='/topic/show?id=0081289832' target=_blank style='color:#2F92EE;'>#asthma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2898, encryptionId=0081289832, topicName=asthma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9b30126, createdName=skhzy, createdTime=Wed Aug 04 22:56:42 CST 2021, time=2021-08-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1329447, encodeId=9a07132944e2d, content=<a href='/topic/show?id=bb96232801' target=_blank style='color:#2F92EE;'>#ALL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2328, encryptionId=bb96232801, topicName=ALL)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/C2EFD5CFB07FE291138AD4FD0C98E3DE/100, createdBy=e3d52500031, createdName=膀胱癌, createdTime=Mon Dec 28 06:56:42 CST 2020, time=2020-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1361147, encodeId=89ac136114eaf, content=<a href='/topic/show?id=3e891034351c' target=_blank style='color:#2F92EE;'>#鼻塞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103435, encryptionId=3e891034351c, topicName=鼻塞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6779163, createdName=liuhuangbo, createdTime=Mon Dec 28 06:56:42 CST 2020, time=2020-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=911453, encodeId=d01f911453bc, content=很好的文章,学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=115, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201226/95ac6d022b194200b46211c8dd67d7d4/d7639abce33d42f18edacbf9c1818b2b.jpg, createdBy=1c242248512, createdName=医路顺丰, createdTime=Sun Dec 27 22:41:06 CST 2020, time=2020-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=911212, encodeId=44a291121214, content=学习了。, beContent=null, objectType=article, channel=null, level=null, likeNumber=146, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d6274853329, createdName=936368183, createdTime=Sun Dec 27 10:49:47 CST 2020, time=2020-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=911125, encodeId=f18d911125a1, content=好文章!, beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160806/IMG57A5698BDB0244113.jpg, createdBy=32a91358059, createdName=jyzxjiangqin, createdTime=Sat Dec 26 19:10:02 CST 2020, time=2020-12-26, status=1, ipAttribution=)]
    2020-12-27 医路顺丰

    很好的文章,学习了

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=1712649, encodeId=8c091e12649a1, content=<a href='/topic/show?id=9a1c289680' target=_blank style='color:#2F92EE;'>#AST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2896, encryptionId=9a1c289680, topicName=AST)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8b9831894722, createdName=ms24272190615788285182, createdTime=Tue Sep 07 01:56:42 CST 2021, time=2021-09-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1977162, encodeId=a54419e716258, content=<a href='/topic/show?id=0081289832' target=_blank style='color:#2F92EE;'>#asthma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2898, encryptionId=0081289832, topicName=asthma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9b30126, createdName=skhzy, createdTime=Wed Aug 04 22:56:42 CST 2021, time=2021-08-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1329447, encodeId=9a07132944e2d, content=<a href='/topic/show?id=bb96232801' target=_blank style='color:#2F92EE;'>#ALL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2328, encryptionId=bb96232801, topicName=ALL)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/C2EFD5CFB07FE291138AD4FD0C98E3DE/100, createdBy=e3d52500031, createdName=膀胱癌, createdTime=Mon Dec 28 06:56:42 CST 2020, time=2020-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1361147, encodeId=89ac136114eaf, content=<a href='/topic/show?id=3e891034351c' target=_blank style='color:#2F92EE;'>#鼻塞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103435, encryptionId=3e891034351c, topicName=鼻塞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6779163, createdName=liuhuangbo, createdTime=Mon Dec 28 06:56:42 CST 2020, time=2020-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=911453, encodeId=d01f911453bc, content=很好的文章,学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=115, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201226/95ac6d022b194200b46211c8dd67d7d4/d7639abce33d42f18edacbf9c1818b2b.jpg, createdBy=1c242248512, createdName=医路顺丰, createdTime=Sun Dec 27 22:41:06 CST 2020, time=2020-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=911212, encodeId=44a291121214, content=学习了。, beContent=null, objectType=article, channel=null, level=null, likeNumber=146, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d6274853329, createdName=936368183, createdTime=Sun Dec 27 10:49:47 CST 2020, time=2020-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=911125, encodeId=f18d911125a1, content=好文章!, beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160806/IMG57A5698BDB0244113.jpg, createdBy=32a91358059, createdName=jyzxjiangqin, createdTime=Sat Dec 26 19:10:02 CST 2020, time=2020-12-26, status=1, ipAttribution=)]
    2020-12-27 936368183

    学习了。

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=1712649, encodeId=8c091e12649a1, content=<a href='/topic/show?id=9a1c289680' target=_blank style='color:#2F92EE;'>#AST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2896, encryptionId=9a1c289680, topicName=AST)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8b9831894722, createdName=ms24272190615788285182, createdTime=Tue Sep 07 01:56:42 CST 2021, time=2021-09-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1977162, encodeId=a54419e716258, content=<a href='/topic/show?id=0081289832' target=_blank style='color:#2F92EE;'>#asthma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2898, encryptionId=0081289832, topicName=asthma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9b30126, createdName=skhzy, createdTime=Wed Aug 04 22:56:42 CST 2021, time=2021-08-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1329447, encodeId=9a07132944e2d, content=<a href='/topic/show?id=bb96232801' target=_blank style='color:#2F92EE;'>#ALL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2328, encryptionId=bb96232801, topicName=ALL)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/C2EFD5CFB07FE291138AD4FD0C98E3DE/100, createdBy=e3d52500031, createdName=膀胱癌, createdTime=Mon Dec 28 06:56:42 CST 2020, time=2020-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1361147, encodeId=89ac136114eaf, content=<a href='/topic/show?id=3e891034351c' target=_blank style='color:#2F92EE;'>#鼻塞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103435, encryptionId=3e891034351c, topicName=鼻塞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6779163, createdName=liuhuangbo, createdTime=Mon Dec 28 06:56:42 CST 2020, time=2020-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=911453, encodeId=d01f911453bc, content=很好的文章,学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=115, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201226/95ac6d022b194200b46211c8dd67d7d4/d7639abce33d42f18edacbf9c1818b2b.jpg, createdBy=1c242248512, createdName=医路顺丰, createdTime=Sun Dec 27 22:41:06 CST 2020, time=2020-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=911212, encodeId=44a291121214, content=学习了。, beContent=null, objectType=article, channel=null, level=null, likeNumber=146, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d6274853329, createdName=936368183, createdTime=Sun Dec 27 10:49:47 CST 2020, time=2020-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=911125, encodeId=f18d911125a1, content=好文章!, beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160806/IMG57A5698BDB0244113.jpg, createdBy=32a91358059, createdName=jyzxjiangqin, createdTime=Sat Dec 26 19:10:02 CST 2020, time=2020-12-26, status=1, ipAttribution=)]
    2020-12-26 jyzxjiangqin

    好文章!

    0

相关资讯

Sci Signal:中药蛇床子登上Science子刊封面,我国学者证实蛇床子可舒张气道、抑制哮喘,并解析其分子机制

气道高反应性是指气道对多种刺激因子出现过强或过早的收缩反应,这一症状在哮喘病人中尤为常见,严重时可导致病人呼吸困难。常规使用的肾上腺素受体激动剂虽可有效抑制气道高反应性,但容易产生耐药反应。

Am J Respir Crit Care Med:奥马利珠单抗对阿司匹林加重的呼吸系统疾病的疗效如何?

阿司匹林加重型呼吸道疾病的特点是严重的哮喘、非甾体抗炎药物过敏、鼻息肉病和白三烯过度分泌。系统性皮质激素治疗不能完全抑制终生的阿司匹林超敏反应。目前,尚未有随机试验探究奥马利珠单抗对阿司匹林加重的呼吸

J Asthma:奥马珠单抗可改善哮喘的症状

抗免疫球蛋白E单克隆抗体奥马珠单抗用于治疗重症哮喘,具有改善气道炎症的潜力。然而,奥马利珠单抗改善上气道炎症的效果尚未完全阐明。本研究旨在探究上、下气道炎症与奥马珠单抗治疗反应的关系。

阿斯利康的TSLP单抗tezepelumab治疗严重哮喘,III期临床成功

“tezepelumab不同其他哮喘生物药物,是通过阻断胸腺基质淋巴细胞生成素(TSLP)发挥作用。”

Thorax:夜间轮班工作与哮喘风险增加相关

哮喘和轮班工作具有较高患病率和同时发生,这些结果对公共卫生的影响是深远的。需要进行纵向随访研究,以明确是否修改轮班工作时间表,以减少发生诸如哮喘等炎症性疾病的风险。

Respir Res:抗IL5可有效治疗某些特定的重症哮喘患者

血液和痰液嗜酸性粒细胞数量的增加与哮喘较高的发作频率和严重程度的增加有关。在临床试验中,靶向白细胞介素-5是重症嗜酸粒细胞性哮喘患者的有效治疗策略。自2017年初以来,我院已有26名患者开始服用瑞舒单

Baidu
map
Baidu
map
Baidu
map